Brain+ A/S informed that the company has released an updated version of its digital product, CST-Therapist Companion, which supports dementia coordinators deliver Cognitive Stimulation Therapy (CST) to people with dementia. CST is an evidence based and worldwide recommended non-pharmaceutical therapy that can reduce cognitive decline and improve social skills as well as quality-of-life for people with early Alzheimer's. Brain+' CST-Therapist Companion can reduce preparation time for CST therapists and support a more consistent high-quality delivery of the therapy. CST-Therapist Companion was introduced to the Danish market in November 2022 as a minimum viable product (MVP) version.

Based on feedback from users, the company has now made a number of product upgrades and released a new version 1.2 with improved user features and image quality, upgraded interface compatibility and extended licensing management. Brain+' main development activities have been focused on the development of a substantial upgrade of the CST-Therapist Companion product. This upgrade is referred to as product version 2.0, as it represents a considerable increase in terms of the value delivered to dementia therapists offering CST.

CST-Therapist Companion v2.0 will include a substantially increased amount of high-quality and specialist validated CST content and features that enables customization of therapy sessions to adapt to the specific characteristics of a given group of people with dementia receiving the therapy. In this regard, the content in CST-Therapist Companion v 2.0 can be adapted to provide the best possible CST support given the level of cognitive ability of the group, which can vary significantly in people with mild to moderate dementia. Other relevant characteristics to consider for the optimal therapy delivery are age, physical abilities, and social preferences.

CST-Therapist Companion V2.0 is in the final stage of development and a clinical usability trial of the product is planned to start in Denmark in October 2023. The trial will be conducted in collaboration with the main dementia care and CST specialists in Denmark with participation of six municipalities. Brain+ expects to introduce a commercial version of CST-Therapist Companion v two.0 in H1 2024 following final product adjustments to be based on the outcome of the clinical trial.